Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipoic acid as adjunctive therapy for sepsis-related moderate-to-severe ARDS (Phase II, randomized, double-blind, placebo-controlled)
ChiCTR2500115388Phase 4Not yet recruiting
- Sponsor
- Weifang People's Hospital
- Start
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of alpha-lipoic acid in acute respiratory distress syndrome (ARDS) and sepsis (2 arms), sponsored by Weifang People's Hospital. Primary endpoint: Change in PaO2/FiO2 at day 7. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
alpha-lipoic acid
03
Conditions
acute respiratory distress syndrome (ARDS)sepsis
Beyond the preview
Go deeper on ChiCTR2500115388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115388.